Form 8-K - Current report:
SEC Accession No. 0001558370-25-000526
Filing Date
2025-01-30
Accepted
2025-01-30 07:30:11
Documents
16
Period of Report
2025-01-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mxct-20250130x8k.htm   iXBRL 8-K 38176
2 EX-99.1 mxct-20250130xex99d1.htm EX-99.1 23158
3 GRAPHIC mxct-20250130xex99d1001.jpg GRAPHIC 3772
4 GRAPHIC mxct-20250130xex99d1002.jpg GRAPHIC 5774
  Complete submission text file 0001558370-25-000526.txt   205755

Data Files

Seq Description Document Type Size
5 EX-101.SCH mxct-20250130.xsd EX-101.SCH 3417
6 EX-101.LAB mxct-20250130_lab.xml EX-101.LAB 16578
7 EX-101.PRE mxct-20250130_pre.xml EX-101.PRE 10717
18 EXTRACTED XBRL INSTANCE DOCUMENT mxct-20250130x8k_htm.xml XML 5020
Mailing Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850
Business Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 301-517-5556
MAXCYTE, INC. (Filer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40674 | Film No.: 25571181
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)